Renal cell carcinoma natural history, complications, and prognosis
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing. Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
Renal cell carcinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Renal cell carcinoma natural history, complications, and prognosis On the Web |
|
American Roentgen Ray Society Images of Renal cell carcinoma natural history, complications, and prognosis |
|
FDA on Renal cell carcinoma natural history, complications, and prognosis |
|
CDC on Renal cell carcinoma natural history, complications, and prognosis |
|
Renal cell carcinoma natural history, complications, and prognosis in the news |
|
Blogs on Renal cell carcinoma natural history, complications, and prognosis |
Overview
Natural History
Complications
Patients with renal cell carcinoma are at risk of hepatic vein thrombosis or Budd-Chiari syndrome
Prognosis
The outcome varies depending on the size of the tumor, whether it is confined to the kidney or not, and the presence or absence of metastatic spread. The Furhman grading, which measures the aggressiveness of the tumor, may also be associated with survival, although the data is not as strong to support this.
The five year survival rate is around 90-95% for tumors less than 4 cm. For larger tumors confined to the kidney without venous invasion, survival is still relatively good at 80-85%. For tumors that extend through the renal capsule and out of the local fascial investments, the survivability reduces to near 60%. If it has metastasized to the lymph nodes, the 5-year survival is around 5 % to 15 %. If it has spread metastatically to other organs, the 5-year survival rate is less than 5 %.
For those that have tumor recurrence after surgery, the prognosis is generally poor. Renal cell carcinoma does not generally respond to chemotherapy or radiation. Immunotherapy, which attempts to induce the body to attack the remaining cancer cells, has shown promise. Recent trials are testing newer agents, though the current complete remission rate with these approaches are still low, around 12-20% in most series.
Every year, about 12,000 people in the US die from renal cell carcinoma.